CL2020000363A1 - Inhibidores macrocíclicos de mcl-1 y métodos de uso. - Google Patents

Inhibidores macrocíclicos de mcl-1 y métodos de uso.

Info

Publication number
CL2020000363A1
CL2020000363A1 CL2020000363A CL2020000363A CL2020000363A1 CL 2020000363 A1 CL2020000363 A1 CL 2020000363A1 CL 2020000363 A CL2020000363 A CL 2020000363A CL 2020000363 A CL2020000363 A CL 2020000363A CL 2020000363 A1 CL2020000363 A1 CL 2020000363A1
Authority
CL
Chile
Prior art keywords
inhibitors
methods
mcl
macrocyclic
macrocyclic mcl
Prior art date
Application number
CL2020000363A
Other languages
English (en)
Inventor
Zhi-Fu Tao
Xilu Wang
Aaron Kunzer
Gerard Sullivan
Wilfried Braje
George Doherty
Katja Jantos
Cheng Ji
Andrew Judd
Anthony Mastracchio
Xiaohong Song
Andrew Souers
Jesse Teske
Michael Wendt
Thomas Penning
Andreas Kling
Frauke Pohlki
Chunqiu Lai
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of CL2020000363A1 publication Critical patent/CL2020000363A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE DIVULGACIÓN SE REFIERE A INHIBIDORES DE LA PROTEÍNA DE DIFERENCIACIÓN CELULAR DE LEUCEMIA 5 MIELOIDE INDUCIDA (MCL-1), EN DONDE A2, A3, A4, A6, A7, A8, A15, RA, R5, R10A, R10B, R11, R12, R13, R14, W, X, E Y TIENEN CUALQUIERA DE LOS VALORES DEFINIDOS EN LA MEMORIA DESCRIPTIVA, Y SALES ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO DE ESTOS , QUE SON ÚTILES COMO AGENTES EN EL TRATAMIENTO DE ENFERMEDADES Y AFECCIONES, INCLUIDO EL CÁNCER. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE LA FÓRMULA (I) .
CL2020000363A 2017-08-15 2020-02-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. CL2020000363A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30

Publications (1)

Publication Number Publication Date
CL2020000363A1 true CL2020000363A1 (es) 2020-06-12

Family

ID=65362347

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000363A CL2020000363A1 (es) 2017-08-15 2020-02-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso.
CL2020002943A CL2020002943A1 (es) 2017-08-15 2020-11-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002943A CL2020002943A1 (es) 2017-08-15 2020-11-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020

Country Status (22)

Country Link
US (4) US10676485B2 (es)
EP (2) EP3988555A1 (es)
JP (1) JP2020531433A (es)
KR (1) KR20200041942A (es)
CN (1) CN111818917A (es)
AU (1) AU2018316620A1 (es)
BR (1) BR112020003180A2 (es)
CA (1) CA3073112A1 (es)
CL (2) CL2020000363A1 (es)
CO (1) CO2020002678A2 (es)
CR (1) CR20200124A (es)
EC (1) ECSP20018703A (es)
IL (1) IL272681A (es)
MX (1) MX2020001717A (es)
PE (1) PE20200837A1 (es)
PH (1) PH12020500327A1 (es)
RU (1) RU2020110517A (es)
SG (2) SG11202001182QA (es)
TW (1) TW201920194A (es)
UA (1) UA126586C2 (es)
UY (1) UY37843A (es)
WO (1) WO2019035911A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414390B2 (en) 2017-09-07 2022-08-16 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032045B (zh) 2017-08-15 2023-08-15 安吉奥斯医药品有限公司 用于治疗血液病症的丙酮酸激酶激活剂
EP3668502A4 (en) * 2017-08-15 2021-01-13 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CR20200124A (es) * 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
US20190055264A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
CA3138058A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
PE20251072A1 (es) 2022-05-20 2025-04-10 Novartis Ag Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗ｃｄ７抗體藥物結合物及其使用方法
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101667822B1 (ko) * 2008-04-30 2016-10-19 내셔날 헬스 리서치 인스티튜트 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SMT202000249T1 (it) 2016-04-22 2020-07-08 Astrazeneca Ab Inibitori di mcl1 macrociclici per il trattamento di cancro
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
IL266198B2 (en) 2016-10-28 2023-11-01 Servier Lab Liposomal formulation for use in cancer treatment
EP3567043B1 (en) 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
US20190055264A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
CR20200124A (es) * 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
EP3668502A4 (en) * 2017-08-15 2021-01-13 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414390B2 (en) 2017-09-07 2022-08-16 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof
US12234211B2 (en) 2017-09-07 2025-02-25 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US12616690B2 (en) 2017-09-07 2026-05-05 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Also Published As

Publication number Publication date
MX2020001717A (es) 2020-10-08
US20250092062A1 (en) 2025-03-20
RU2020110517A3 (es) 2022-03-23
UA126586C2 (uk) 2022-11-02
JP2020531433A (ja) 2020-11-05
PE20200837A1 (es) 2020-08-13
AU2018316620A1 (en) 2020-03-12
KR20200041942A (ko) 2020-04-22
RU2020110517A (ru) 2021-09-16
SG11202001182QA (en) 2020-03-30
IL272681A (en) 2020-03-31
CA3073112A1 (en) 2019-02-21
EP3988555A1 (en) 2022-04-27
US20230183261A1 (en) 2023-06-15
EP3652184A1 (en) 2020-05-20
BR112020003180A2 (pt) 2020-09-15
US20200325153A1 (en) 2020-10-15
EP3652184A4 (en) 2020-05-20
ECSP20018703A (es) 2020-04-22
PH12020500327A1 (en) 2020-10-12
UY37843A (es) 2019-03-29
TW201920194A (zh) 2019-06-01
CR20200124A (es) 2020-09-28
CO2020002678A2 (es) 2020-08-10
CN111818917A (zh) 2020-10-23
WO2019035911A1 (en) 2019-02-21
SG10202106345VA (en) 2021-07-29
US10676485B2 (en) 2020-06-09
US20190144465A1 (en) 2019-05-16
CL2020002943A1 (es) 2021-03-12

Similar Documents

Publication Publication Date Title
ECSP20018703A (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CO2018011064A2 (es) Inhibidores de bromodominios
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
DOP2015000305A (es) Inhibidores de bromodominios
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
TH1801006379A (th) ตัวยับยั้งโบรโมโดเมน